 |
 |
 |
 |
 |
|
|
|
|
|
|
RHEI continually seeks to build its pipeline by in-licensing approved or late stage products. RHEI focuses on specific therapeutic areas such as oncology, women’s health, infectious diseases, dermatology. Its Chinese operations manage the regulatory process, clinical development and sale of branded pharmaceuticals. For additional information, please contact: Geert Cauwenbergh |
|